

Table of content

Table of content	5
Acknowledgements	9
Abstract	11
Abbreviations	13
1. General introduction	17
2. Synthesis and optimization of small molecule inhibitors of the iron transporter DMT1	21
Abstract	21
2.1. Introduction.....	21
2.1.1. Divalent metal ion transporter 1 (DMT1) and iron homeostasis	22
2.1.1.1. Iron	22
2.1.1.2. Iron transport	22
2.1.1.3. Divalent Metal ion Transporter 1	23
2.1.2. Small molecule inhibitor of DMT1 in literature	24
2.1.3. Goal of the project	25
2.2. Results	26
2.2.1. Principle of radiolabelled iron uptake assay	26
2.2.2. Characterization of mechanism of inhibition of known inhibitors.....	26
2.2.2.1. Synthesis of 9.....	27
2.2.2.2. Synthesis of dibenzofuran compounds.....	27
2.2.2.3. Iron uptake assay results for 12 and 13.....	28
2.2.2.4. Kinetics studies for 12 and 13.....	29
2.2.3. Synthesis of benzylthiourea inhibitors for structure-based drug design	31
2.2.3.1. Synthesis of analogues of 5 and 10.	32
2.2.3.2. Soaking experiments	33
2.2.3.3. Analogues of 20.....	34
2.2.3.4. Outlook.....	35
2.2.4. Optimization of pyrimidinone 11.....	35
2.2.4.1. Synthesis and biological results of analogues of 11.....	35
2.2.4.2. Biological activity for 38.....	38
2.2.4.3. Synthesis of analogues of 38	39
2.2.4.4. Mechanism of inhibition of 38.....	40
2.2.4.5. Metal chelation	42
2.2.5. Discovery of a new inhibitor by fragment library screening	45
2.2.5.1. Screening of the fragment library.....	45
2.2.5.2. Hit compounds	46

2.2.5.3. Analogues of 59	47
2.3. Conclusion	48
Contribution	49
3. Discovery of a new inhibitor of ZIP8 by Fragment Based Lead Discovery	51
Abstract	51
3.1. Introduction	51
3.1.1. Fragment-based lead discovery	51
3.1.2. Zinc homeostasis and Zip8	52
3.1.3. ZIP8 and osteoarthritis	55
3.1.4. Project Goal	55
3.1.5. Principle of the ZIP8 assay	55
3.2. Design of the library	56
3.2.1. Generated Databases (GDB)	56
3.2.2. Fragment Database FDB17	57
3.2.3. Fragment library	57
3.2.4. Selection of the Fragment library	58
3.2.5. Comparison of the libraries	59
3.3. Results	60
3.3.1. Screening of the selection	60
3.3.2. Hit compounds	61
3.3.3. Screening of analogues of <i>rac</i> -78	62
3.3.4. Synthesis of the two enantiomers of <i>rac</i> -78	65
3.3.5. Off targets activities	66
3.4. Conclusion	68
Contributions	69
4. Chemical probes for targeting astrocytic vesicular monoamine transporter 2 (VMAT2)	71
Abstract	71
4.1. Introduction	71
4.1.1. Astrocytes	71
4.1.1.1. Roles of astrocytes	71
4.1.1.2. Astrocytes and VMAT2 in dopamine homeostasis	72
4.1.2. Vesicular monoamine transporter 2 (VMAT2)	73
4.1.3. Goal of the project	73
4.1.4. Design of the probe	73
4.1.4.1. Drug carrier: Sulforhodamine B (SRB)	73
4.1.4.2. VMAT2 inhibitor: Tetrabenazine (TBZ)	74
4.2. Results	75

4.2.1. Synthesis of an ester derivative of TBZ	75
4.2.1.1. Design and synthesis of an ester derivative of TBZ	75
4.2.1.2. Synthesis of deuterated analogues of 112 for pharmacokinetic study.	77
4.2.2. Synthesis of amide analogues of 112	79
4.2.2.1. Design of the linkers	79
4.2.2.2. Synthesis of analogues of 112	80
4.2.2.3. Imaging in brain slides	82
4.2.3. Design and synthesis of a probe for FRET experiments	83
4.2.3.1. Design of the probe	83
4.2.3.2. Synthesis of two SRB derivatives	84
4.3. Conclusion	85
Contributions	86
5. Development of prodrugs targeting LPAAT β	87
Abstract	87
5.1. Introduction	87
5.1.1. Goal of the project	87
5.1.2. Lysophosphatidic acid acyl transferases (LPAATs)	88
5.2. Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT- β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2 ⁹⁷ .	89
5.3. Aminopropyl derivative of 153.	91
5.4. Prodrug approach	93
5.4.1. Peptide Prodrug approach	93
5.4.1.1. Cathepsin B	94
5.4.1.2. Zinc metalloproteinases (MMPs)	94
5.4.2. Alkyl chain approach	95
5.4.3. Synthesis	96
5.4.3.1. Synthesis of peptide prodrugs	96
5.4.3.2. Synthesis of lauric derivative of 172	97
5.4.4. Binding to bovine serum albumin (BSA)	97
5.4.5. Cytotoxicity assay	99
5.5. Conclusion	100
Contribution	100
6. Annexes	101
6.1. Annexe of Chapter 2	101
6.2. Annexe of Chapter 3	102
7. Experimental Part	105
7.1. General remarks	105
7.1.1. Synthesis	105

7.1.2.	Commercial compounds.....	106
7.2.	Experimental Part for Chapter 2.....	106
7.2.1.	Chemistry	106
7.2.2.	HPLC purity of the final compounds of chapter 2.....	125
7.2.3.	Biology.....	126
7.2.3.1.	Radiolabelled iron uptake assay	126
7.2.3.2.	Fluorescence cadmium uptake assay (FLIPr assay).....	127
7.2.4.	ITC experiments.....	127
7.2.5.	pKa measurement	128
7.3.	Experimental Part for Chapter 3.....	128
7.3.1.	Chemistry	128
7.3.2.	HPLC purity of the final compounds of chapter 3.....	137
7.3.3.	Biology: Fluorescence cadmium uptake assay (FLIPr assay)	138
7.4.	Experimental Part for Chapter 4.....	138
7.4.1.	Synthesis.....	138
7.4.2.	HPLC purity of the final compound of chapter 4	164
7.5.	Experimental Part for Chapter 5.....	164
7.5.1.	Chemistry	164
7.5.2.	HPLC purity of the final compounds of chapter 4.....	171
7.5.3.	Cytotoxicity assay	171
7.5.4.	Fluorescent assay	172
8.	Bibliography.....	173
	Communicated results	184